SAUDI ARABIA Trends and Developments Contributed by: Saud Alromi, Mostafa Ihab, Mohamed Ramadan and Saleh Albadry, Mohammed AlDhabaan & Partners Eversheds Sutherland
• clinical trials – necessary for vaccines to ensure their effectiveness and safety; and • the submission process – involves online submis ‑ sion, technical and business validation, evaluation/ inspection and pricing review. Key Players in the Saudi Healthcare Sector Several key entities play significant roles in the Saudi healthcare sector. • The Ministry of Health (MoH): Regulates all health ‑ care-related activities and services within the country. The MoH oversees the implementation of healthcare policies, ensures compliance with regu ‑ latory standards and works to improve the quality of healthcare services. The MoH is also responsible for launching health clusters, integrated networks of healthcare providers that aim to improve access to healthcare services and promote preventive care. • The National Unified Company for Medical Sup ‑ plies (NUPCO): Responsible for centralised government procurement of pharmaceuticals, medical equipment and supplies. NUPCO collects requirements from government agencies, issues tenders and manages the supply chain and logis ‑ tics for public healthcare facilities. This centralised approach ensures that public healthcare providers have access to the necessary medical supplies and pharmaceuticals. • The SFDA: Monitors and controls imports and dis ‑ tribution of medical devices, pharmaceuticals and food products. • The Cooperative Council of Health Insurance (CCHI): Regulates Saudi Arabia’s health insur ‑ ance sector. The CCHI ensures that health insur ‑ ance providers comply with regulatory standards and provides oversight to protect the interests of insured individuals. The CCHI’s role is particularly important as Saudi Arabia moves towards a more privatised healthcare system, with increased reli ‑ ance on private health insurance. • The National Center for Privatization (NCP): Ena ‑ bles the privatisation of certain government assets and services. The NCP works to create an environ ‑ ment conducive to private sector participation, facilitating public-private partnerships (PPPs) and
ensuring that privatisation initiatives align with the goals of Vision 2030. • SAIP: Regulates, enhances and protects the King ‑ dom’s IP landscape. • The Health Holding Company (HHC): Manages the day-to-day administration of health services from the MoH and provides services through primary healthcare development programmes. The HHC provides healthcare services through primary healthcare development programmes, includ ‑ ing digital health and virtual medical care. This approach aims to improve the efficiency and qual ‑ ity of healthcare services in Saudi Arabia. Impact of Privatization on Life Sciences & Pharma IP Litigation Saudi Arabia’s Vision 2030 aims to transform the healthcare sector through privatisation and increased private sector participation. The government plans to invest billions of dollars to develop healthcare infra ‑ structure, reorganise and privatise health services and insurance, and expand e-health services. This transformation is expected to create significant com ‑ mercial opportunities for both local and international companies. Privatisation initiatives include the introduction of PPP in various healthcare areas, such as primary care, hos ‑ pitals, medical cities, laboratories, radiology, pharma ‑ cies, rehabilitation, long-term care and home care. The privatisation of the healthcare sector and the introduction of PPPs have created new opportunities and challenges for IP litigation. Companies involved in PPP projects must navigate complex regulatory and IP landscapes to protect their interests. The shift towards privatisation also means that private companies will need to be more vigilant in protecting their IP rights and ensuring compliance with regulatory standards. IP Protection and Enforcement IP protection is critical for fostering innovation and attracting investment in the pharmaceutical sector. Saudi Arabia has made significant improvements in its IP protection and enforcement procedures. The SFDA and SAIP have developed guidelines to support pharmaceutical manufacturers in registering
211 CHAMBERS.COM
Powered by FlippingBook